Methotrexate-induced Hypersensitivity Pneumonitis appearing after 30 years of use: a case report

Mashal Salehi1,2, Robertha Miller3,4, Myint Khaing3,4

  • 1Department of Medicine, NYC Health and Hospitals/Harlem, Columbia University, New York, USA. Salehi.MashaL@yahoo.com.

Abstract

Insights

This case report details a rare instance of hypersensitivity pneumonitis caused by methotrexate after 30 years of use. Early diagnosis and treatment with steroids led to significant recovery, highlighting that drug-induced lung disease can manifest late.

Area of Science:

  • Pulmonology
  • Rheumatology
  • Clinical Pharmacology

Background:

  • Methotrexate (MTX) is a widely used disease-modifying antirheumatic drug (DMARD).
  • MTX is associated with various pulmonary complications, including hypersensitivity pneumonitis (HP).
  • MTX-induced HP typically occurs within the first year of treatment.

Observation:

  • A 77-year-old woman with rheumatoid arthritis developed progressive dyspnea and cough after 30 years of daily low-dose oral MTX.
  • Clinical presentation included fever, tachycardia, hypoxia, and characteristic lung imaging findings.
  • Laboratory results showed eosinophilia and elevated ESR, with negative infectious workup.

Findings:

  • The patient was diagnosed with methotrexate-induced hypersensitivity pneumonitis.
  • Discontinuation of MTX and initiation of high-dose corticosteroids resulted in rapid clinical and radiological improvement.
  • This represents the first reported case of MTX-induced HP occurring after 30 years of continuous therapy.

Implications:

  • Methotrexate-induced hypersensitivity pneumonitis can occur even after prolonged therapy.
  • Prompt recognition and management are critical for reversing MTX-induced lung disease.
  • Clinicians should maintain a high index of suspicion for MTX-HP in patients with respiratory symptoms, regardless of treatment duration.

Related Concept Videos

Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
1.1K
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
288
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
688
Drug Toxicity: Allergic Reactions01:30

Drug Toxicity: Allergic Reactions

Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial...
64
Pneumothorax-II01:27

Pneumothorax-II

Pneumothorax is a medical condition defined by the buildup of air in the pleural space between the lungs and the chest wall. This accumulation of air can lead to partial or complete lung collapse, resulting in a range of clinical manifestations. Understanding the clinical presentation and effective management strategies is crucial for healthcare professionals in providing timely and appropriate care to individuals with pneumothorax.
Clinical Manifestations:
1.2K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
604